OR14-2 Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial

We have previously demonstrated that a 12-week addition of liraglutide to insulin therapy in patients with type 1 diabetes (T1D) results in an improvement in glycemic control, weight loss and a reduction in systolic blood pressure (SBP). We have now conducted a 6 month randomized study investigating...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Endocr Soc
Autori principali: Dandona, Paresh, Ghanim, Husam, Hejna, Jeanne, Green, Kelly, Makdissi, Antoine, Borowski, Robert, Kuhadiya, Nitesh, Batra, Manav, Chaudhuri, Ajay
Natura: Artigo
Lingua:Inglês
Pubblicazione: Endocrine Society 2019
Soggetti:
Diabetes Mellitus and Glucose Metabolism
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555035/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR14-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi